{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:19:19Z","timestamp":1769015959235,"version":"3.49.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,13]]},"DOI":"10.7759\/cureus.48717","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:59:41Z","timestamp":1699869581000},"source":"Crossref","is-referenced-by-count":3,"title":["The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment"],"prefix":"10.7759","author":[{"given":"Lu","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"YuMei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vallish","family":"BN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32594-0","article-title":"Iron deficiency","volume":"397","author":"Pasricha SR","year":"2021","unstructured":"Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021, 397:233-48. 10.1016\/s0140-6736(20)32594-0","journal-title":"Lancet"},{"key":"ref2","unstructured":"Global nutrition targets 2025. anaemia policy brief. (2014). https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NHD-14.4."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/nu14122449","article-title":"Attention should be paid to adolescent girl anemia in China: based on China nutrition and health surveillance (2015-2017)","volume":"14","author":"Li S","year":"2022","unstructured":"Li S, Zhao L, Yu D, Ren H. Attention should be paid to adolescent girl anemia in China: based on China nutrition and health surveillance (2015-2017). Nutrients. 2022, 14:10.3390\/nu14122449","journal-title":"Nutrients"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61381-0","article-title":"Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study","volume":"378","author":"Musallam KM","year":"2011","unstructured":"Musallam KM, Tamim HM, Richards T, et al.. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011, 378:1396-407. 10.1016\/s0140-6736(11)61381-0","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2013.00585","article-title":"Perinatal iron deficiency and neurocognitive development","volume":"7","author":"Radlowski EC","year":"2013","unstructured":"Radlowski EC, Johnson RW. Perinatal iron deficiency and neurocognitive development. Front Hum Neurosci. 2013, 7:585. 10.3389\/fnhum.2013.00585","journal-title":"Front Hum Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(18)30078-0","article-title":"Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis","volume":"6","author":"Daru J","year":"2018","unstructured":"Daru J, Zamora J, Fern\u00e1ndez-F\u00e9lix BM, et al.. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. Lancet Glob Health. 2018, 6:e548-54. 10.1016\/s2214-109x(18)30078-0","journal-title":"Lancet Glob Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.06.066","article-title":"Meta-analysis of efficacy and safety of intravenous iron in patients with iron deficiency and heart failure with reduced ejection fraction","volume":"202","author":"Hamza M","year":"2023","unstructured":"Hamza M, Sattar Y, Manasrah N, et al.. Meta-analysis of efficacy and safety of intravenous iron in patients with iron deficiency and heart failure with reduced ejection fraction. Am J Cardiol. 2023, 202:119-30. 10.1016\/j.amjcard.2023.06.066","journal-title":"Am J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab050","article-title":"Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia","volume":"36","author":"Guedes M","year":"2021","unstructured":"Guedes M, Muenz D, Zee J, et al.. Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrol Dial Transplant. 2021, 36:1694-703. 10.1093\/ndt\/gfab050","journal-title":"Nephrol Dial Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24820","article-title":"Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management","volume":"92","author":"Cappellini MD","year":"2017","unstructured":"Cappellini MD, Comin-Colet J, de Francisco A, et al.. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017, 92:1068-78. 10.1002\/ajh.24820","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00160-6","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021","volume":"10","year":"2023","unstructured":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021. findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2023, 10:e713-34. 10.1016\/S2352-3026(23)00160-6","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry","volume":"23","author":"Becher PM","year":"2021","unstructured":"Becher PM, Schrage B, Benson L, et al.. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2021, 23:1844-54. 10.1002\/ejhf.2338","journal-title":"Eur J Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.2096-2681.2019.05.012","article-title":"How to improve the safety of surgery for patients with anemia","volume":"3","author":"Zhisong W","year":"2019","unstructured":"Zhisong W, Haizhong S, Shuozeng D. How to improve the safety of surgery for patients with anemia. Anesthesia Safety and Quality Control. 2019, 3:296-8. 10.3969\/j.issn.2096-2681.2019.05.012","journal-title":"Anesthesia Safety and Quality Control"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2017.11.1126","article-title":"Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report","volume":"41","author":"Allen RP","year":"2018","unstructured":"Allen RP, Picchietti DL, Auerbach M, et al.. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome\/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018, 41:27-44. 10.1016\/j.sleep.2017.11.1126","journal-title":"Sleep Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14173","article-title":"Postdonation iron replacement for maintaining iron stores in female whole blood donors in routine donor practice: results of two feasibility studies in Australia","volume":"57","author":"Pasricha SR","year":"2017","unstructured":"Pasricha SR, Marks DC, Salvin H, Brama T, Keller AJ, Pink J, Speedy J. Postdonation iron replacement for maintaining iron stores in female whole blood donors in routine donor practice: results of two feasibility studies in Australia. Transfusion. 2017, 57:1922-9. 10.1111\/trf.14173","journal-title":"Transfusion"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005721","article-title":"Recommendations from the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)","volume":"277","author":"Shander A","year":"2023","unstructured":"Shander A, Corwin HL, Meier J, et al.. Recommendations from the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS). Ann Surg. 2023, 277:581-90. 10.1097\/SLA.0000000000005721","journal-title":"Ann Surg"},{"key":"ref16","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hematopoietic growth factors. (2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass AU","year":"2015","unstructured":"Dignass AU, Gasche C, Bettenworth D, et al.. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015, 9:211-22. 10.1093\/ecco-jcc\/jju009","journal-title":"J Crohns Colitis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102.S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75535-2","article-title":"Intravenous iron infusion as an alternative to minimize blood transfusion in peri-operative patients","volume":"10","author":"Ionescu A","year":"2020","unstructured":"Ionescu A, Sharma A, Kundnani NR, et al.. Intravenous iron infusion as an alternative to minimize blood transfusion in peri-operative patients. Sci Rep. 2020, 10:18403. 10.1038\/s41598-020-75535-2","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein I","year":"2021","unstructured":"Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021, 20:757-69. 10.1080\/14740338.2021.1912010","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","unstructured":"Ferinject (ferric carboxymaltose). (2023). Accessed. October 16, 2023: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc#gref."},{"key":"ref22","unstructured":"Ferric derisomaltose Pharmacosmos 100 mg\/ml solution for injection\/infusion. (2023). Accessed. October 16, 2023: https:\/\/www.medicines.org.uk\/emc\/product\/5676\/smpc."},{"key":"ref23","unstructured":"Venofer (iron sucrose) 20 mg iron \/ ml, solution for injection or concentrate for solution for infusion. (2021). Accessed. October 16, 2023: https:\/\/www.medicines.org.uk\/emc\/product\/5911\/smpc."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach M","year":"2019","unstructured":"Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019, 94:1007-14. 10.1002\/ajh.25564","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia","volume":"92","author":"Derman R","year":"2017","unstructured":"Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017, 92:286-91. 10.1002\/ajh.24633","journal-title":"Am J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-3384.2022.07.006","article-title":"Real-world study of iron sucrose in the treatment of iron deficiency anemia","volume":"20","author":"Wu DP","year":"2022","unstructured":"Wu DP, Xuan JW. Real-world study of iron sucrose in the treatment of iron deficiency anemia. J Clin Drug Therapy. 2022, 20:32-9. 10.3969\/j.issn.1672-3384.2022.07.006","journal-title":"J Clin Drug Therapy"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron Isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf M","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al.. Effects of iron Isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020, 323:432-43. 10.1001\/jama.2019.22450","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller H","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, et al.. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023, 72:644-53. 10.1136\/gutjnl-2022-327897","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose","volume":"107","author":"Schaefer B","year":"2022","unstructured":"Schaefer B, Zoller H, Wolf M. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2022, 107:1009-19. 10.1210\/clinem\/dgab852","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ygh2.415","article-title":"Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose - real world experience from a tertiary centre in the UK","volume":"2","author":"Fragkos KC","year":"2020","unstructured":"Fragkos KC, Sehgal V, Rogers J, et al.. Hypophosphataemia after intravenous iron therapy with ferric carboxymaltose - real world experience from a tertiary centre in the UK. GastroHep. 2020, 2:205-14. 10.1002\/ygh2.415","journal-title":"GastroHep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18979","article-title":"Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-a 3-year experience from a single institution in Singapore","volume":"202","author":"Chu Z","year":"2023","unstructured":"Chu Z, Cushway T, Wong M, et al.. Incidence and predictors of hypophosphataemia after ferric carboxymaltose use-a 3-year experience from a single institution in Singapore. Br J Haematol. 2023, 202:1199-204. 10.1111\/bjh.18979","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/cc9215","article-title":"Treatment of hypophosphatemia in the intensive care unit: a review","volume":"14","author":"Geerse DA","year":"2010","unstructured":"Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010, 14:R147. 10.1186\/cc9215","journal-title":"Crit Care"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.050","article-title":"Blood and bone loser","volume":"152","author":"Schaefer B","year":"2017","unstructured":"Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017, 152:e5-6. 10.1053\/j.gastro.2016.09.050","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2014.10.016","article-title":"[Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect]","volume":"145","author":"S\u00e1nchez Gonz\u00e1lez R","year":"2015","unstructured":"S\u00e1nchez Gonz\u00e1lez R, Ternavasio-de la Vega HG, Moralejo Alonso L, In\u00e9s Revuelta S, Fuertes Mart\u00edn A. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect]. Med Clin (Barc). 2015, 145:108-11. 10.1016\/j.medcli.2014.10.016","journal-title":"Med Clin (Barc)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy S","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015, 2015:468675. 10.1155\/2015\/468675","journal-title":"Int J Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller H","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017, 26:266-75. 10.1097\/MNH.0000000000000329","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer B","year":"2022","unstructured":"Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022, 154:116202. 10.1016\/j.bone.2021.116202","journal-title":"Bone"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports","volume":"37","author":"Vilaca T","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. 2022, 37:1188-99. 10.1002\/jbmr.4558","journal-title":"J Bone Miner Res"},{"key":"ref39","unstructured":"Drug safety update. (2020). https.\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/936767\/Nov-2020-DSU-P...."},{"key":"ref40","unstructured":"INJECTAFER\u00ae (ferric carboxymaltose injection). (2021). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203565s014lbl.pdf."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2018.01038","article-title":"Development of health technology assessment in China: new challenges","volume":"12","author":"Chen Y","year":"2018","unstructured":"Chen Y, He Y, Chi X, Wei Y, Shi L. Development of health technology assessment in China: new challenges. Biosci Trends. 2018, 12:102-8. 10.5582\/bst.2018.01038","journal-title":"Biosci Trends"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau D","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al.. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Health. 2022, 25:3-9. 10.1016\/j.jval.2021.11.1351","journal-title":"Value Health"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1017\/s0266462303000011","article-title":"Toward transparency in health technology assessment: a checklist for HTA reports","volume":"19","author":"Hailey D","year":"2003","unstructured":"Hailey D. Toward transparency in health technology assessment: a checklist for HTA reports. Int J Technol Assess Health Care. 2003, 19:1-7. 10.1017\/s0266462303000011","journal-title":"Int J Technol Assess Health Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2015.0803","article-title":"Indirect comparisons and network meta-analyses","volume":"112","author":"Kiefer C","year":"2015","unstructured":"Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses. Dtsch Arztebl Int. 2015, 112:803-8. 10.3238\/arztebl.2015.0803","journal-title":"Dtsch Arztebl Int"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/ph13050085","article-title":"The impact of iron supplementation for treating anemia in patients with chronic kidney disease: results from pairwise and network meta-analyses of randomized controlled trials","volume":"13","author":"Adler M","year":"2020","unstructured":"Adler M, Herrera-G\u00f3mez F, Mart\u00edn-Garc\u00eda D, Gavid M, \u00c1lvarez FJ, Ochoa-Sangrador C. The impact of iron supplementation for treating anemia in patients with chronic kidney disease: results from pairwise and network meta-analyses of randomized controlled trials. Pharmaceuticals (Basel). 2020, 13:10.3390\/ph13050085","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan A","year":"2017","unstructured":"Aksan A, I\u015f\u0131k H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017, 45:1303-18. 10.1111\/apt.14043","journal-title":"Aliment Pharmacol Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2020.07.002","article-title":"Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis","volume":"34","author":"Bellos I","year":"2020","unstructured":"Bellos I, Frountzas M, Pergialiotis V. Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network meta-analysis. Transfus Med Rev. 2020, 34:188-94. 10.1016\/j.tmrv.2020.07.002","journal-title":"Transfus Med Rev"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02591-1","article-title":"Incidence of hypophosphatemia after intravenous administration of iron: a matching-adjusted indirect comparison of data from Japanese randomized controlled trials","volume":"40","author":"Fukumoto S","year":"2023","unstructured":"Fukumoto S, Murata T, Osuga Y, Pollock RF. Incidence of hypophosphatemia after intravenous administration of iron: a matching-adjusted indirect comparison of data from Japanese randomized controlled trials. Adv Ther. 2023, 40:4877-88. 10.1007\/s12325-023-02591-1","journal-title":"Adv Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2065092","article-title":"Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose","volume":"25","author":"Hu S","year":"2022","unstructured":"Hu S, Liu L, Pollock RF, P\u00f6hlmann J, Wu D, Zhang Y. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. J Med Econ. 2022, 25:561-70. 10.1080\/13696998.2022.2065092","journal-title":"J Med Econ"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01548-2","article-title":"A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose","volume":"45","author":"Kennedy NA","year":"2023","unstructured":"Kennedy NA, Achebe MM, Biggar P, P\u00f6hlmann J, Pollock RF. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm. 2023, 45:604-12. 10.1007\/s11096-023-01548-2","journal-title":"Int J Clin Pharm"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1575202","article-title":"A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment","volume":"12","author":"Pollock RF","year":"2019","unstructured":"Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019, 12:129-36. 10.1080\/17474086.2019.1575202","journal-title":"Expert Rev Hematol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1709437","article-title":"Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia","volume":"13","author":"Pollock RF","year":"2020","unstructured":"Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020, 13:187-95. 10.1080\/17474086.2020.1709437","journal-title":"Expert Rev Hematol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02242-x","article-title":"A systematic review, meta-analysis, and indirect comparison of blindly adjudicated cardiovascular event incidence with ferric derisomaltose, ferric carboxymaltose, and iron sucrose","volume":"39","author":"Pollock RF","year":"2022","unstructured":"Pollock RF, Kalra PA, Kalra PR, Ahmed FZ. A systematic review, meta-analysis, and indirect comparison of blindly adjudicated cardiovascular event incidence with ferric derisomaltose, ferric carboxymaltose, and iron sucrose. Adv Ther. 2022, 39:4678-91. 10.1007\/s12325-022-02242-x","journal-title":"Adv Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer B","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021, 87:2256-73. 10.1111\/bcp.14643","journal-title":"Br J Clin Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.6039\/j.issn.1001-0408.2022.24.19","article-title":"Iron isomaltoside for the treatment of iron deficiency anemia: a rapid health technology assessment","volume":"33","author":"Liu X","year":"2022","unstructured":"Liu X, Gao S, Qi R, Du G, Liu G. Iron isomaltoside for the treatment of iron deficiency anemia: a rapid health technology assessment. Chin Pharm. 2022, 33:3040-4. 10.6039\/j.issn.1001-0408.2022.24.19","journal-title":"Chin Pharm"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-3384.2022.12.006","article-title":"Network meta-analysis of different intravenous irons in the treatment of anemia","volume":"20","author":"Huang Y","year":"2022","unstructured":"Huang Y, Su N, Li D, He J-h, Wu F-b, Yang T. Network meta-analysis of different intravenous irons in the treatment of anemia. Clin Med J. 2022, 20:29-34. 10.3969\/j.issn.1672-3384.2022.12.006","journal-title":"Clin Med J"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03401-0","article-title":"Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study","volume":"116","author":"Kawabata H","year":"2022","unstructured":"Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. Int J Hematol. 2022, 116:647-58. 10.1007\/s12185-022-03401-0","journal-title":"Int J Hematol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2501-8","article-title":"Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study","volume":"109","author":"Ikuta K","year":"2019","unstructured":"Ikuta K, Hanashi H, Hirai K, et al.. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019, 109:41-9. 10.1007\/s12185-018-2501-8","journal-title":"Int J Hematol"},{"key":"ref61","unstructured":"CADTH Canadian Drug Expert Committee Recommendation. Iron Isomaltoside 1000 (Monoferric \u2014 Pharmacosmos A\/S). CADTH Canadian Drug Expert Committee Recommendation: Iron Isomaltoside 1000 (Monoferric \u2014 Pharmacosmos A\/S): Indication: For the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy The diagnosis must be based on laboratory tests. Canadian Agency for Drugs and Technologies in Health, Ottawa. (2020). Accessed: 16 October 2023: https:\/\/pubmed.ncbi.nlm.nih.gov\/33231954\/."},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-02029-9","article-title":"AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals","volume":"11","author":"Li L","year":"2022","unstructured":"Li L, Asemota I, Liu B, et al.. AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals. Syst Rev. 2022, 11:147. 10.1186\/s13643-022-02029-9","journal-title":"Syst Rev"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S306823","article-title":"Evaluation of the cost-effectiveness of iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease in the UK","volume":"13","author":"Aksan A","year":"2021","unstructured":"Aksan A, Beales IL, Baxter G, de Arellano AR, Gavata S, Valentine WJ, Hunt B. Evaluation of the cost-effectiveness of iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease in the UK. Clinicoecon Outcomes Res. 2021, 13:541-52. 10.2147\/CEOR.S306823","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01553-1","article-title":"Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland","volume":"38","author":"Aksan A","year":"2021","unstructured":"Aksan A, Schoepfer A, Juillerat P, et al.. Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland. Adv Ther. 2021, 38:660-77. 10.1007\/s12325-020-01553-1","journal-title":"Adv Ther"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9991311","article-title":"Cost-effectiveness of intravenous iron formulations in patients with iron deficiency anaemia and inflammatory bowel disease, in a Swedish regional setting using real-world tender prices","volume":"2022","author":"Ramirez de Arellano A","year":"2022","unstructured":"Ramirez de Arellano A, Norton N, Enkusson D, Oldsberg L, Thomson Y, Lilja M, Aksan A. Cost-effectiveness of intravenous iron formulations in patients with iron deficiency anaemia and inflammatory bowel disease, in a Swedish regional setting using real-world tender prices. GastroHep. 2022, 2022:10.1155\/2022\/9991311","journal-title":"GastroHep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-02000-5","article-title":"Letter to the editor regarding \u2018iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland\u2019","volume":"39","author":"Mu\u00f1oz M","year":"2022","unstructured":"Mu\u00f1oz M, Reinisch W. Letter to the editor regarding \u2018iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland\u2019. Adv Ther. 2022, 39:811-4. 10.1007\/s12325-021-02000-5","journal-title":"Adv Ther"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01241-0","article-title":"Development of a resource impact model for clinics treating pre-operative iron deficiency anemia in Ireland","volume":"37","author":"Loughnane F","year":"2020","unstructured":"Loughnane F, Muduma G, Pollock RF. Development of a resource impact model for clinics treating pre-operative iron deficiency anemia in Ireland. Adv Ther. 2020, 37:1218-32. 10.1007\/s12325-020-01241-0","journal-title":"Adv Ther"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0827-5","article-title":"An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark","volume":"35","author":"Pollock RF","year":"2018","unstructured":"Pollock RF, Muduma G. An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark. Adv Ther. 2018, 35:2128-37. 10.1007\/s12325-018-0827-5","journal-title":"Adv Ther"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S284959","article-title":"An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland","volume":"13","author":"Pollock RF","year":"2021","unstructured":"Pollock RF, Muduma G. An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland. Clinicoecon Outcomes Res. 2021, 13:9-18. 10.2147\/CEOR.S284959","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1745535","article-title":"A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom","volume":"23","author":"Pollock RF","year":"2020","unstructured":"Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020, 23:751-9. 10.1080\/13696998.2020.1745535","journal-title":"J Med Econ"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S17536","article-title":"A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000","volume":"7","author":"Bhandari S","year":"2011","unstructured":"Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag. 2011, 7:103-13. 10.2147\/TCRM.S17536","journal-title":"Ther Clin Risk Manag"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of\u00a0iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari S","year":"2021","unstructured":"Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of\u00a0iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2021, 36:111-20. 10.1093\/ndt\/gfaa011","journal-title":"Nephrol Dial Transplant"},{"key":"ref73","article-title":"Pharmacoeconomic review report: iron isomaltoside 1000 (Monoferric)","year":"2020","unstructured":"Pharmacoeconomic review report. iron isomaltoside 1000 (Monoferric). Canadian Agency for Drugs and Technologies in Health, Ottawa, ON; 2020."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf M","year":"2018","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018, 3:10.1172\/jci.insight.124486","journal-title":"JCI Insight"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx310","article-title":"A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy","volume":"33","author":"Huang LL","year":"2018","unstructured":"Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC, McMahon LP. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018, 33:1628-35. 10.1093\/ndt\/gfx310","journal-title":"Nephrol Dial Transplant"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer B","year":"2020","unstructured":"Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020, 75:100862. 10.1016\/j.mam.2020.100862","journal-title":"Mol Aspects Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel EA","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011, 96:3541-9. 10.1210\/jc.2011-1239","journal-title":"J Clin Endocrinol Metab"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2016.217","article-title":"Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients","volume":"71","author":"Tan SJ","year":"2017","unstructured":"Tan SJ, Satake S, Smith ER, Toussaint ND, Hewitson TD, Holt SG. Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. Eur J Clin Nutr. 2017, 71:180-4. 10.1038\/ejcn.2016.217","journal-title":"Eur J Clin Nutr"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten BJ","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009, 94:2332-7. 10.1210\/jc.2008-2396","journal-title":"J Clin Endocrinol Metab"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager P","year":"2017","unstructured":"Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017, 83:1118-25. 10.1111\/bcp.13189","journal-title":"Br J Clin Pharmacol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy JA","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, et al.. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag. 2020, 16:245-59. 10.2147\/TCRM.S243462","journal-title":"Ther Clin Risk Manag"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-11-3","article-title":"Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review","volume":"10","author":"Kassianides X","year":"2021","unstructured":"Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context. 2021, 10:10.7573\/dic.2020-11-3","journal-title":"Drugs Context"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1989.tb03091.x","article-title":"Hypophosphatemia. Causes and clinical consequences","volume":"3","author":"Forrester SD","year":"1989","unstructured":"Forrester SD, Moreland KJ. Hypophosphatemia. Causes and clinical consequences. J Vet Intern Med. 1989, 3:149-59. 10.1111\/j.1939-1676.1989.tb03091.x","journal-title":"J Vet Intern Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011925","article-title":"Fibroblast growth factor 23 and long-term cardiac function: the multi-ethnic study of atherosclerosis","volume":"13","author":"Patel RB","year":"2020","unstructured":"Patel RB, Ning H, de Boer IH, et al.. Fibroblast growth factor 23 and long-term cardiac function: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2020, 13:e011925. 10.1161\/CIRCIMAGING.120.011925","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul C","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, et al.. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121:4393-408. 10.1172\/JCI46122","journal-title":"J Clin Invest"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.13.15","article-title":"Iron (III) isomaltoside 1000","volume":"6","author":"Mace TA","year":"2013","unstructured":"Mace TA, Syed A, Bhandari S. Iron (III) isomaltoside 1000. Expert Rev Hematol. 2013, 6:239-46. 10.1586\/ehm.13.15","journal-title":"Expert Rev Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/201333-the-efficacy-safety-and-economic-outcomes-of-using-ferric-derisomaltose-for-the-management-of-iron-deficiency-in-china-a-rapid-health-technology-assessment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:47Z","timestamp":1707509387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/201333-the-efficacy-safety-and-economic-outcomes-of-using-ferric-derisomaltose-for-the-management-of-iron-deficiency-in-china-a-rapid-health-technology-assessment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":86,"URL":"https:\/\/doi.org\/10.7759\/cureus.48717","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}